Table 2. Total costs and component costs of managing different forms of TB at 3 treatment centers, Canada, July 2010–June 2016*.
Characteristic | Cost, in 2020 Canadian dollars |
|||
---|---|---|---|---|
TB infection, n = 90 | DS TB, n = 90 | INHR TB, n = 71 | MDR TB, n = 62 | |
Median (IQR) costs† | ||||
Total costs | 804 (587–1,205) | 12,148 (4,388–24,842) | 19,319 (7,117–41,318) | 119,014 (80,642–164,015) |
Diagnosis | 267 (217–376) | 701 (526–1,026) | 819 (657–1,049) | 1,083 (925–1,331) |
Treatment | 521 (377–771) | 2,145 (1,614–3,187) | 2,864 (2,263–3,919) | 61,426 (29,840–108,703) |
Posttreatment monitoring | 0 (0–0) | 139 (28–283) | 130 (39–195) | 193 (39–341) |
Hospitalization | 0 (0–0) | 2,600 (0–15,524) | 10,400 (0–27,227) | 41,216 (35,178–55,766) |
Associated with public health interventions |
0 (0–0) |
3,174 (632–5,232) |
2,885 (1,111–6,174) |
6,399 (4,657–6,798) |
Mean costs‡ | ||||
Total costs | 917 | 15,772 | 32,343 | 131,780 |
Diagnosis | 308 | 789 | 860 | 1,233 |
Treatment | 587 | 2,585 | 4,641 | 74,709 |
Posttreatment monitoring | 22 | 181 | 166 | 243 |
Hospitalization | 0 | 8,587 | 19,963 | 48,791 |
Associated with public health interventions | 0 | 3,630 | 6,713 | 6,804 |
*AFB, acid-fast bacilli; DS, drug-susceptible; INHR, isoniazid-resistant; IQR, interquartile range; MDR, multidrug-resistant; TB, tuberculosis. †Component values may not sum to the total cost value because of use of medians. ‡Component values may not sum to the total cost value because of rounding.